Sealbond Ltd - 21 Nov 2025 Form 4 Insider Report for Dogwood Therapeutics, Inc. (DWTX)

Reporting relationship: Director, Other*, 10%+ Owner
Issuer ticker: DWTX
Reported as of: 21 Nov 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Nov 2025, 17:39:55 UTC
Prior SEC filing: 17 Oct 2024
Source filing: View source filing
Reporting owner signature: /s/ Wong Wun Lam, Director of Sealbond Limited

Key filing fact

Sealbond Ltd filed Form 4 for Dogwood Therapeutics, Inc. (DWTX) on 25 Nov 2025.

Key facts

This page summarizes Sealbond Ltd's Form 4 filing for Dogwood Therapeutics, Inc. (DWTX).
4 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 25 Nov 2025, 17:39.

Change

Previous filing in this sequence was filed on 17 Oct 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0002040446 Primary reporting owner

Sealbond Ltd

Relationship: Director, Other*, 10%+ Owner
Address: 2 DAI FU STREET,, TAI PO INDUSTRIAL ESTATE, NEW TERRITORIES, HONG KONG
Signature: /s/ Wong Wun Lam, Director of Sealbond Limited
Signature date: 25 Nov 2025

CIK 0002061651

Conjoint Inc.

Relationship: Director, Other*, 10%+ Owner
Address: 2 DAI FU STREET,, TAI PO INDUSTRIAL ESTATE, NEW TERRITORIES, HONG KONG
Signature: /s/ Yu Ying Choi Alan Abel, Director of Conjoint Inc.
Signature date: 25 Nov 2025

CIK 0001297567

CK Life Sciences Intl (Holdings) Inc

Relationship: Director, Other*, 10%+ Owner
Address: 2 DAI FU STREET,, TAI PO INDUSTRIAL ESTATE, NEW TERRITORIES, HONG KONG
Signature: /s/ Yu Ying Choi Alan Abel, Director of CK Life Sciences Int'l., (Holdings) Inc.
Signature date: 25 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DWTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +21,610,950
Change %: +10224%
Price
Shares after: 21,822,333
Date: 21 Nov 2025
Ownership: Direct
Footnotes: F1, F2

DWTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +2,842,638
Change %
Price
Shares after: 2,842,638
Date: 21 Nov 2025
Ownership: By Conjoint Inc.
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DWTX transaction Derivative

Series A Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -2,161
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 21 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 21,610,950
Exercise price
Footnotes: F1, F2, F4

DWTX transaction Derivative

Series A-1 Preferred Stock

Conversion of derivative security

Transaction value: $0
Shares: -284
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 21 Nov 2025
Ownership: By Conjoint Inc.
Underlying class: Common Stock
Underlying amount: 2,842,638
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

On November 21, 2025, following stockholder approval of the conversion of the Issuer's Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A Preferred Stock") and the Issuer's Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share (the "Series A-1 Preferred Stock" and together with the Series A Preferred Stock, the "Preferred Stock"), into shares of the Issuer's Common Stock, par value $0.0001 per share ("Common Stock"), each share of Preferred Stock automatically converted into 10,000 shares of Common Stock. The shares of Preferred Stock had no expiration date.

Footnote F2

Sealbond Limited, a British Virgin Islands limited company ("Sealbond"), is a wholly-owned subsidiary of Kamfull Limited, a British Virgin Islands limited company ("Kamfull"). Kamfull is a wholly owned subsidiary of Biotech Strategic Holdings Ltd, a British Virgin Islands limited company ("Biotech Strategic). Biotech Strategic is a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc., a company incorporated in the Cayman Islands with limited liability ("CKLS"). CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F3

Shares are held directly by Conjoint Inc., a Delaware corporation ("Conjoint"). Conjoint is a wholly owned subsidiary of Honglad Limited, a British Virgin Islands limited company ("Honglad"). Honglad is a wholly owned subsidiary of ENSO Resources Limited, a British Virgin Islands limited company ("ENSO Resources"). ENSO Resources is a wholly owned subsidiary of CKLS. CKLS disclaims Section 16 beneficial ownership of the securities reported herein, except to the extent, if any, of its pecuniary interest in such securities, and nothing contained in this report shall be deemed an omission that CKLS is the beneficial owner of such securities for Section 16 or any other purpose.

Footnote F4

Includes 52.7096 shares of Series A Preferred Stock previously issued to Sealbond as a payment-in-kind dividend that was exempt from Section 16 pursuant to Rule 16a-9 of the Securities Exchange Act of 1934, as amended.

SEC remarks

Mr. Yu Ying Choi Alan Abel ("Mr. Yu"), the Deputy Chairman of CKLS, and Dr. Toh Kean Meng Melvin ("Dr. Toh"), the Vice President and Chief Scientific Officer and Executive Director of CKLS, have been appointed to the board of directors of the Issuer, and each of Mr. Yu and Dr. Toh have been deputized to represent the Reporting Person on the board of directors. By virtue of Mr. Yu and Dr. Toh's representation, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the Reporting Person may be deemed a director by deputization of the Issuer. Mr. Yu and Dr. Toh have filed separate Section 16 reports disclosing securities of the Issuer that each may respectively be deemed to beneficially own for Section 16 purposes.